Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients
with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812)
or placebo. Each patient's participation will last approximately 41 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborator:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC